Previous reports of the RAPID-axSpA trial ( NCT@ ) described the efficacy and safety of certolizumab pegol ( CZP ) over @ weeks in patients with axial spondyloarthritis ( SpA ) , including ankylosing spondylitis ( AS ) and nonradiographic axial SpA .